Felicia Castriota1, Johanna Acevedo2, Catterina Ferreccio2, Allan H Smith3, Jane Liaw3, Martyn T Smith1, Craig Steinmaus4. 1. Environmental Health Sciences Division, School of Public Health, University of California, Berkeley, CA, United States. 2. Pontificia Universidad Católica de Chile, Advanced Center for Chronic Diseases, ACCDiS, Santiago, Chile. 3. Arsenic Health Effects Research Program, School of Public Health, University of California, Berkeley, CA, United States. 4. Arsenic Health Effects Research Program, School of Public Health, University of California, Berkeley, CA, United States; Office of Environmental Health Hazard Assessment, California Environmental Protection Agency, Oakland, CA, United States. Electronic address: craigs@berkeley.edu.
Abstract
BACKGROUND: The prevalence of type 2 diabetes (T2D) has nearly doubled since 1980. Elevated body mass index (BMI) is the leading risk factor for T2D, mediated by inflammation and oxidative stress. Arsenic shares similar pathogenic processes, and may contribute to hyperglycemia and β-cell dysfunction. OBJECTIVES: We assessed a unique situation of individuals living in Northern Chile with data on lifetime arsenic exposure to evaluate the relationship between arsenic and T2D, and investigate possible interactions with BMI. METHODS: We analyzed data collected from October 2007-December 2010 from an arsenic-cancer case-control study. Information on self-reported weight, height, smoking, diet, and other factors were obtained. Diabetes was defined by self-reported physician-diagnoses or use of hypoglycemic medication. A total of 1053 individuals, 234 diabetics and 819 without known diabetes were included. RESULTS: The T2D odds ratio (OR) for cumulative arsenic exposures of 610-5279 and ≥ 5280 μg/L-years occurring 40 years or more before interview were 0.97 (95% CI: 0.66-1.43) and 1.53 (95% CI: 1.05-2.23), respectively. Arsenic-associated T2D ORs were greater in subjects with increased BMIs. For example, the ORs for past cumulative exposures ≥ 5280 μg/L-years was 1.45 (95% CI: 0.74-2.84) in participants with BMIs < 25 kg/m2 but 2.64 (95% CI: 1.14-6.11) in those with BMIs ≥ 30 kg/m2 (synergy index = 2.49, 95% CI: 0.87-7.09). Results were similar when people with cancer were excluded. CONCLUSIONS: These findings identify increased odds of T2D with arsenic exposure, which are significantly increased in individuals with excess BMI.
BACKGROUND: The prevalence of type 2 diabetes (T2D) has nearly doubled since 1980. Elevated body mass index (BMI) is the leading risk factor for T2D, mediated by inflammation and oxidative stress. Arsenic shares similar pathogenic processes, and may contribute to hyperglycemia and β-cell dysfunction. OBJECTIVES: We assessed a unique situation of individuals living in Northern Chile with data on lifetime arsenic exposure to evaluate the relationship between arsenic and T2D, and investigate possible interactions with BMI. METHODS: We analyzed data collected from October 2007-December 2010 from an arsenic-cancer case-control study. Information on self-reported weight, height, smoking, diet, and other factors were obtained. Diabetes was defined by self-reported physician-diagnoses or use of hypoglycemic medication. A total of 1053 individuals, 234 diabetics and 819 without known diabetes were included. RESULTS: The T2D odds ratio (OR) for cumulative arsenic exposures of 610-5279 and ≥ 5280 μg/L-years occurring 40 years or more before interview were 0.97 (95% CI: 0.66-1.43) and 1.53 (95% CI: 1.05-2.23), respectively. Arsenic-associated T2D ORs were greater in subjects with increased BMIs. For example, the ORs for past cumulative exposures ≥ 5280 μg/L-years was 1.45 (95% CI: 0.74-2.84) in participants with BMIs < 25 kg/m2 but 2.64 (95% CI: 1.14-6.11) in those with BMIs ≥ 30 kg/m2 (synergy index = 2.49, 95% CI: 0.87-7.09). Results were similar when people with cancer were excluded. CONCLUSIONS: These findings identify increased odds of T2D with arsenic exposure, which are significantly increased in individuals with excess BMI.
Authors: Timothy R Koves; John R Ussher; Robert C Noland; Dorothy Slentz; Merrie Mosedale; Olga Ilkayeva; James Bain; Robert Stevens; Jason R B Dyck; Christopher B Newgard; Gary D Lopaschuk; Deborah M Muoio Journal: Cell Metab Date: 2008-01 Impact factor: 27.287
Authors: Craig Steinmaus; Felicia Castriota; Catterina Ferreccio; Allan H Smith; Yan Yuan; Jane Liaw; Johanna Acevedo; Liliana Pérez; Rodrigo Meza; Sergio Calcagno; Ricardo Uauy; Martyn T Smith Journal: Environ Res Date: 2015-10 Impact factor: 6.498
Authors: Elizabeth A Maull; Habibul Ahsan; Joshua Edwards; Matthew P Longnecker; Ana Navas-Acien; Jingbo Pi; Ellen K Silbergeld; Miroslav Styblo; Chin-Hsiao Tseng; Kristina A Thayer; Dana Loomis Journal: Environ Health Perspect Date: 2012-08-10 Impact factor: 9.031
Authors: Stephanie M Eick; Catterina Ferreccio; Johanna Acevedo; Felicia Castriota; José F Cordero; Taehyun Roh; Allan H Smith; Martyn T Smith; Craig Steinmaus Journal: Environ Res Date: 2019-03-06 Impact factor: 6.498
Authors: James G Xenakis; Christelle Douillet; Timothy A Bell; Pablo Hock; Joseph Farrington; Tianyi Liu; Caroline E Y Murphy; Avani Saraswatula; Ginger D Shaw; Gustavo Nativio; Qing Shi; Abhishek Venkatratnam; Fei Zou; Rebecca C Fry; Miroslav Stýblo; Fernando Pardo-Manuel de Villena Journal: Mamm Genome Date: 2022-07-11 Impact factor: 3.224
Authors: Sara M Amolegbe; Danielle J Carlin; Heather F Henry; Michelle L Heacock; Brittany A Trottier; William A Suk Journal: Exp Biol Med (Maywood) Date: 2022-03-07
Authors: Madelyn C Huang; Christelle Douillet; Ellen N Dover; Chongben Zhang; Rowan Beck; Ahmad Tejan-Sie; Sergey A Krupenko; Miroslav Stýblo Journal: Environ Health Perspect Date: 2018-12 Impact factor: 9.031
Authors: Felicia Castriota; Linda Rieswijk; Sarah Dahlberg; Michele A La Merrill; Craig Steinmaus; Martyn T Smith; Jen-Chywan Wang Journal: Environ Health Perspect Date: 2020-01-03 Impact factor: 9.031
Authors: Felicia Castriota; Peter-James H Zushin; Sylvia S Sanchez; Rachael V Phillips; Alan Hubbard; Andreas Stahl; Martyn T Smith; Jen-Chywan Wang; Michele A La Merrill Journal: Am J Physiol Endocrinol Metab Date: 2020-02-11 Impact factor: 4.310